JP7384667B2 - 多価ワクチン組成物 - Google Patents

多価ワクチン組成物 Download PDF

Info

Publication number
JP7384667B2
JP7384667B2 JP2019532214A JP2019532214A JP7384667B2 JP 7384667 B2 JP7384667 B2 JP 7384667B2 JP 2019532214 A JP2019532214 A JP 2019532214A JP 2019532214 A JP2019532214 A JP 2019532214A JP 7384667 B2 JP7384667 B2 JP 7384667B2
Authority
JP
Japan
Prior art keywords
antigen
type
present
combination
ipv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019532214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526635A (ja
JP2019526635A5 (https=
Inventor
マラサカント デレ ラジーブ
シャンカー ピサル サンブハジ
カマラジ ザデ ジャグディシュ
ナラヤン サバル ラジェンドラ
バプラオ カダム ラビンドラ
サンジーブ カンブル アブヒジート
チアン パオミン
グラス ロジャー
Original Assignee
セラム インスティテュート オブ インディア プライベート リミティド
ザ ユナイテッド ステイツ オブ アメリカ，アズ リプレゼンティッド バイ ザ セクレタリー，ディパートメント オブ ヘルス アンド ヒューマン サービシーズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラム インスティテュート オブ インディア プライベート リミティド, ザ ユナイテッド ステイツ オブ アメリカ，アズ リプレゼンティッド バイ ザ セクレタリー，ディパートメント オブ ヘルス アンド ヒューマン サービシーズ filed Critical セラム インスティテュート オブ インディア プライベート リミティド
Publication of JP2019526635A publication Critical patent/JP2019526635A/ja
Publication of JP2019526635A5 publication Critical patent/JP2019526635A5/ja
Priority to JP2021118038A priority Critical patent/JP2021181445A/ja
Priority to JP2023174503A priority patent/JP2024009899A/ja
Application granted granted Critical
Publication of JP7384667B2 publication Critical patent/JP7384667B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
JP2019532214A 2016-08-26 2017-08-24 多価ワクチン組成物 Active JP7384667B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021118038A JP2021181445A (ja) 2016-08-26 2021-07-16 多価ワクチン組成物
JP2023174503A JP2024009899A (ja) 2016-08-26 2023-10-06 多価ワクチン組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201621029037 2016-08-26
IN201621029037 2016-08-26
PCT/IB2017/055100 WO2018037365A1 (en) 2016-08-26 2017-08-24 Multivalent vaccine composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021118038A Division JP2021181445A (ja) 2016-08-26 2021-07-16 多価ワクチン組成物

Publications (3)

Publication Number Publication Date
JP2019526635A JP2019526635A (ja) 2019-09-19
JP2019526635A5 JP2019526635A5 (https=) 2019-10-31
JP7384667B2 true JP7384667B2 (ja) 2023-11-21

Family

ID=60083359

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019532214A Active JP7384667B2 (ja) 2016-08-26 2017-08-24 多価ワクチン組成物
JP2021118038A Pending JP2021181445A (ja) 2016-08-26 2021-07-16 多価ワクチン組成物
JP2023174503A Pending JP2024009899A (ja) 2016-08-26 2023-10-06 多価ワクチン組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021118038A Pending JP2021181445A (ja) 2016-08-26 2021-07-16 多価ワクチン組成物
JP2023174503A Pending JP2024009899A (ja) 2016-08-26 2023-10-06 多価ワクチン組成物

Country Status (17)

Country Link
US (1) US11235054B2 (https=)
EP (1) EP3503917B1 (https=)
JP (3) JP7384667B2 (https=)
KR (1) KR102607295B1 (https=)
CN (1) CN110691611A (https=)
AU (1) AU2017316768B2 (https=)
CA (1) CA3032901A1 (https=)
CU (1) CU24682B1 (https=)
EA (1) EA201900117A1 (https=)
IL (1) IL264605B2 (https=)
MX (1) MX2019001780A (https=)
MY (1) MY191163A (https=)
PE (1) PE20200004A1 (https=)
PH (1) PH12019500404B1 (https=)
SG (1) SG11201900365WA (https=)
UA (1) UA129115C2 (https=)
WO (1) WO2018037365A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201900365WA (en) * 2016-08-26 2019-02-27 Serum Institute Of India Pvt Ltd Multivalent vaccine composition
US11793873B2 (en) 2017-05-10 2023-10-24 University Of Massachusetts Bivalent dengue/hepatitis B vaccines
MX2021004233A (es) * 2018-10-12 2021-08-16 Serum Inst Of India Private Ltd Composicion de vacuna combinada que comprende dosis reducidas del virus inactivado de la polio y metodo de preparacion de la misma.
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008536515A (ja) 2005-04-18 2008-09-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド ワクチンの調製のためのｂ型肝炎ウイルス表面抗原の発現
WO2010132561A2 (en) 2009-05-12 2010-11-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention New human rotavirus strains and vaccines
WO2012093406A2 (en) 2011-01-05 2012-07-12 Bharat Biotech International Limited A combination heptavalent vaccine
WO2016063291A1 (en) 2014-10-07 2016-04-28 Serum Institute Of India Private Limited Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8945582B2 (en) * 2006-09-07 2015-02-03 Glaxosmithkline Biologicals S.A. Vaccine
PE20100365A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
WO2012117377A1 (en) * 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
SG11201900365WA (en) * 2016-08-26 2019-02-27 Serum Institute Of India Pvt Ltd Multivalent vaccine composition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008536515A (ja) 2005-04-18 2008-09-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド ワクチンの調製のためのｂ型肝炎ウイルス表面抗原の発現
WO2010132561A2 (en) 2009-05-12 2010-11-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention New human rotavirus strains and vaccines
WO2012093406A2 (en) 2011-01-05 2012-07-12 Bharat Biotech International Limited A combination heptavalent vaccine
WO2016063291A1 (en) 2014-10-07 2016-04-28 Serum Institute Of India Private Limited Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof

Also Published As

Publication number Publication date
MX2019001780A (es) 2020-01-13
PH12019500404A1 (en) 2020-01-20
PH12019500404B1 (en) 2024-05-15
AU2017316768B2 (en) 2024-04-11
JP2021181445A (ja) 2021-11-25
EA201900117A1 (ru) 2019-09-30
BR112019003419A2 (pt) 2019-05-21
AU2017316768A1 (en) 2019-04-11
NZ751127A (en) 2025-08-29
EP3503917B1 (en) 2024-07-03
IL264605B2 (en) 2023-04-01
US11235054B2 (en) 2022-02-01
US20190175722A1 (en) 2019-06-13
WO2018037365A1 (en) 2018-03-01
CU20190013A7 (es) 2019-10-04
JP2024009899A (ja) 2024-01-23
KR20190142311A (ko) 2019-12-26
SG11201900365WA (en) 2019-02-27
UA129115C2 (uk) 2025-01-22
IL264605B (en) 2022-12-01
IL264605A (en) 2019-02-28
CU24682B1 (es) 2023-10-06
EP3503917A1 (en) 2019-07-03
MY191163A (en) 2022-06-03
PE20200004A1 (es) 2020-01-06
JP2019526635A (ja) 2019-09-19
CN110691611A (zh) 2020-01-14
WO2018037365A8 (en) 2018-09-20
CA3032901A1 (en) 2018-03-01
KR102607295B1 (ko) 2023-11-29

Similar Documents

Publication Publication Date Title
JP2024009899A (ja) 多価ワクチン組成物
US8551451B2 (en) Combination vaccine with acellular pertussis
CN103442730B (zh) 组合七价疫苗
EP2682127A1 (en) Vaccine
CN102196817B (zh) 具有全细胞百日咳的联合疫苗
TW202038995A (zh) 多價疫苗組合物
EA043682B1 (ru) Комбинированная вакцина и способ её производства (варианты)
US11793869B2 (en) Methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof
BR112019003419B1 (pt) Vacina combinada e processo de fabricação de uma vacina combinada
OA21991A (en) Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof.
OA20569A (en) Improved methods for enterovirus inactivation, adjuvant adsorption and dose reduced vaccine compositions obtained thereof.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190808

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200811

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210716

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210716

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210730

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20211005

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20211012

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20211029

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20211102

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220712

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221115

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20221129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230828

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231109

R150 Certificate of patent or registration of utility model

Ref document number: 7384667

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150